DrugPatentWatch Database Preview
Drugs in Development Information for Tivozanib
Drug Development Status for Tivozanib: Patents, clinical trial progress, indications
Tivozanib is an investigational drug.
There have been 31 clinical trials for Tivozanib.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2009.
The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Renal Cell, and Colorectal Neoplasms. The leading clinical trial sponsors are AVEO Pharmaceuticals, Inc., National Comprehensive Cancer Network, and Massachusetts General Hospital.
There are fifteen US patents protecting this investigational drug and one hundred and thirty-nine international patents.
Summary for Tivozanib
| US Patents | 15 |
| International Patents | 139 |
| US Patent Applications | 43 |
| WIPO Patent Applications | 27 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2009-12-01) |
| Vendors | 76 |
Recent Clinical Trials for Tivozanib
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Tivozanib in Combination With Durvalumab in Subjects With Untreated Advanced Hepatocellular Carcinoma | AstraZeneca | Phase 1/Phase 2 |
| A Study of Tivozanib in Combination With Durvalumab in Subjects With Untreated Advanced Hepatocellular Carcinoma | AVEO Pharmaceuticals, Inc. | Phase 1/Phase 2 |
| Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC | Bristol-Myers Squibb | Phase 1/Phase 2 |
Clinical Trial Summary for Tivozanib
Top disease conditions for Tivozanib
Top clinical trial sponsors for Tivozanib
US Patents for Tivozanib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Tivozanib | Start Trial | Quinoline derivatives and quinazoline derivatives having azolyl group | Kirin Beer Kabushiki Kaisha (Tokyo-to, JP) | Start Trial |
| Tivozanib | Start Trial | N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n'-(5-methyl-3-isoxaz- olyl)urea salt in crystalline form | Kirin Beer Kabushiki Kaisha (Tokyo-To, JP) | Start Trial |
| Tivozanib | Start Trial | Quinoline derivatives and quinazoline derivatives having azolyl group | Kirin Beer Kabushiki Kaisha (Tokyo-To, KR) | Start Trial |
| Tivozanib | Start Trial | Tivozanib response prediction | AVEO Pharmaceuticals, Inc. (Cambridge, MA) | Start Trial |
| Tivozanib | Start Trial | Tivozanib response prediction | AVEO Pharmaceuticals, Inc. (Cambridge, MA) | Start Trial |
| Tivozanib | Start Trial | Tivozanib and temsirolimus in combination | AVEO Pharmaceuticals, Inc. (Cambridge, MA) | Start Trial |
| Tivozanib | Start Trial | Fully human anti-VEGF antibodies and methods of using | Schering Corporation (Kenilworth, NJ) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Tivozanib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Tivozanib | Austria | 314361 | 2021-04-27 | Start Trial |
| Tivozanib | Austria | 396988 | 2021-04-27 | Start Trial |
| Tivozanib | Australia | 2002255284 | 2021-04-27 | Start Trial |
| Tivozanib | Brazil | 0209216 | 2021-04-27 | Start Trial |
| Tivozanib | Brazil | PI0209216 | 2021-04-27 | Start Trial |
| Tivozanib | Canada | 2445333 | 2021-04-27 | Start Trial |
| Tivozanib | China | 1273466 | 2021-04-27 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
